Sensory Ataxic Guillain-Barré Syndrome with Dysgeusia after mRNA COVID-19 Vaccination

Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Al...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogata, Shunsuke, Ishii, Yoshito, Asano, Keiichiro, Kobayashi, Erena, Kubota, Shun, Takahashi, Keita, Miyaji, Yosuke, Higashiyama, Yuichi, Joki, Hideto, Doi, Hiroshi, Koga, Michiaki, Takeuchi, Hideyuki, Tanaka, Fumiaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9259306/
https://www.ncbi.nlm.nih.gov/pubmed/35342134
http://dx.doi.org/10.2169/internalmedicine.8967-21
Descripción
Sumario:Guillain-Barré syndrome (GBS) has occasionally occurred in people who have received coronavirus disease 2019 (COVID-19) vaccines. Dysgeusia is rare symptom of GBS. We herein report a rare case of sensory ataxic GBS with dysgeusia just after the second dose of the Pfizer-BioNTech COVID-19 vaccine. Although autoantibodies against glycolipids were not detected, immunotherapy with intravenous immunoglobulin and methylprednisolone pulse therapy effectively ameliorated the symptoms. Our report suggests that the COVID-19 vaccine may induce various clinical subtypes of GBS, including a rare variant with sensory ataxia and dysgeusia.

Ejemplares similares